Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 2.71% signifying low profitability per unit of shareholders funds
The company has declared Positive results for the last 7 consecutive quarters
With ROE of -43.55%, it has a risky valuation with a -10.74 Price to Book Value
Rising Promoter Confidence
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 1,725 Million (Small Cap)
25.00
NA
0.00%
-113.64
-461.83%
-143.89
Total Returns (Price + Dividend) 
Aveanna Healthcare Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News

Aveanna Healthcare Holdings, Inc. Experiences Revision in Stock Evaluation Amid Mixed Financial Metrics
Aveanna Healthcare Holdings, Inc. has recently adjusted its valuation, with a P/E ratio of 25 and low PEG ratio of 0.01. The company shows a ROCE of 13.80%, but has a negative ROE. Its valuation metrics present a mixed comparison with industry peers, indicating an evolving market position.
Read More
Aveanna Healthcare Hits Day Low of $7.81 Amid Price Pressure
Aveanna Healthcare Holdings, Inc. faced a significant stock decline today, reaching an intraday low amid a challenging trading session. Despite recent setbacks, the company has shown strong annual performance compared to broader market indices. However, concerns about its financial health persist, particularly regarding profitability and debt levels.
Read More
Aveanna Healthcare Faces Weak Start with Significant Gap Down Amid Market Concerns
Aveanna Healthcare Holdings, Inc. experienced a notable decline in stock performance, opening with a significant loss. The company's market capitalization is around USD 1,725 million, with concerning financial metrics, including a negative return on equity and a complex debt-to-equity structure. Technical indicators show mixed signals regarding future performance.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2025
Shareholding Compare (%holding) 
Strategic Entities
Held in 37 Schemes (9.97%)
Held by 52 Foreign Institutions (1.53%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 5.44% vs 7.56% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 419.23% vs -82.19% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 6.82% vs 6.02% in Dec 2023
YoY Growth in year ended Dec 2024 is 91.90% vs 79.68% in Dec 2023






